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tively correlated (r¼0.413, p¼0.04).
CONCLUSIONS While a minimal deformation of the waist of the ASD
device is expected due to a relative intentional oversizing, in the
present study the observed deformation of the disks of the device was
not correlated with the deformation of the waist. Therefore potential
mechanisms for this deformation, such as mechanical tension from
adjacent structures, should be investigated in future studies.
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BACKGROUND Drug therapy (DT) for ventricular tachycardia (VT) is
not very effective and is fraught with pro-arrhythmic and other
adverse effects. Catheter ablation (CA) of VT is considered an effective
alternative to DT.
METHODS PubMed, EBSCO and Ovid databases were searched to
identify studies comparing CA and DT for the management of VT in
structural heart disease. Studies reporting outcomes of idiopathic VT
were excluded. Baseline characteristics and outcomes of recurrence of
VT and mortality were extracted from the included studies. Risk ratio
(RR) was calculated for the outcomes of recurrence of VT and mor-
tality using random effects model with 95% conﬁdence intervals (CI).
RESULTS A total of 8 studies (5 randomized studies) met our inclusion
criteria and included 1256 patients, 379 in the CA group and 877 in the
DT group. Follow up times varied from 6 months to 5 years. Heteroge-
neity was assessed by Cochcrane q statistic, which suggested low de-
gree of heterogeneity (I2¼25%). VT recurred in 36% and 54% of the CA
and DT groups, respectively. The overall RR of recurrence of VT was
0.67 (95% CI 0.51 – 0.89) in favor of the CA group and exclusion sensi-
tivity of the individual studies did not alter the above results. Subgroup
analysis including only randomized studies also showed a decreased
recurrence of VT after catheter ablation (RR 0.72, 95% CI 0.52 – 0.99).
Mortality was reported in 6 studies and mortality was signiﬁcantly
lower in the CA group compared to DT group (17% vs 42%). The overall
risk ofmortalitywas signiﬁcantly lower in theCA group (RR0.63, 95%CI
0.47 – 0.85). The decrease in mortality was driven by a single study
(Bunch et al.) Publication biaswas assessed bymeans of trim andﬁll plot
and was deemed to be minimal and moderate for the outcomes of VT
recurrence and mortality, respectively.
CONCLUSIONS The results of this meta-analysis suggest that the risk
of VT recurrence and mortality are decreased by 33% and 37%
respectively with CA of VT compared to DT.
CATEGORIES STRUCTURAL: ElectrophysiologyTCT-743
Safety and Effectiveness of Transcatheter Closure of Ostium Secundum
Atrial Septal Defect Using Atrial Septal Occluder Device Without Balloon
Sizing or Invasive Echocardiogram in Low Health Resource Setting
Uditha I. Hewarathna,1 Naradha W. Kodithuwakku,1
Shanike P. Karunaratne,1 Hgwapl Bandara,1 Thangarajah Kogulan,1
Gnanamoorthy Mayurathan,1 Gamini Weerakoon,1 Ajith I. Kularatne,1
Dinesha T. Ambagaspitiya1
1Teaching Hospital Kandy, Kandy 20000, Sri Lanka
BACKGROUND Transcatheter closure of ostium secundum atrial septal
defect (ASD) by atrial septal occluder (ASO) device is aminimally invasive
and effective alternative to surgical repair of ostium secundum atrial
septal defect. This procedure is routinely been practiced with balloon
sizing and invasive echocardiographic assessment. The sizing balloon
usually costs around USD 600, which is not affordable for most of the
patients in our setting. Amethod of device closurewithout balloon sizing
had been described in recent past. We derived a sizing formula using our
initial results and oversized the device ranging from 4 to 6mm to
maximum ASD diameter measured by transthoracic echocardiogram.
This study was designed to evaluate the safety and effectiveness of
transcatheter closure of ostium secundum atrial septal defect without
balloon sizing or invasive echocardiographic assessment.
METHODS Medical records and followed up data of 128 patients who
underwent transcatheter closure of ostium secundum atrial septal defect
by atrial septal occluder device, from March 2009 to May 2014 were
analyzed. The abovementioned sizing formulawas used for device sizing
whereas ﬂuoroscopy and transthoracic echocardiogram were used for
device positioning and assessing the stability. This procedure was done
under local anesthesia. The patients were followed up with a periodic
clinical and echocardiographic evaluation and procedural out comes and
subsequent complications were retrospectively analyzed.
RESULTS Among 128 patients 68.8% (n¼88) were females and 31.2%
(n¼40) were males. Mean age was 34.713.9 with a range from 13 to 63
years. The mean ASD diameter according to the transthoracic echo-
cardiographic measurement was 17.85.1 mm ranging from 8mm to
30mm. Mean size of ASO device diameter was 22.65.5 mm ranging
from 12mm to 34mm. The ﬁnal success rate of the procedure was 91.4%
(n¼117) and failure rate was 8.6% (n¼11). No major complications such
as thromboembolic events, obstruction of intracardiac structures, car-
diac perforation, device embolization, device erosion and residual
shunting or deaths were reported during the procedure or within one
year follow up period.Minor complicationswere reported in 3.9% (n¼5)
of patients. With the use of above mentioned method, average cost per
patient excluding the device cost was USD 325.
CONCLUSIONS Transcatheter closure of ostium secundum ASD with
ASO device using device sizing formula and non-invasive trans-
thoracic echocardiographic assessment is a feasible, safe and cost
effective method which would be more appropriate for countries with
minimum resources for health care.
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BACKGROUND Surgical myectomy (SM) and alcohol septal ablation
(ASA) are the 2 invasive strategies used to relieve left ventricular
outﬂow tract obstruction (LVOTO) in patients with drug refractory
symptomatic hypertrophic cardiomyopathy (HCM). No randomized
B304 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5trial comparing ASA with SM have been performed. Furthermore, 3 of
the largest studies comparing the 2 procedures were published last
year. Hence, we performed an updated systematic review to compare
ASA and SM. Our primary aim was to compare the efﬁcacy of both
strategies in improving patient’s symptoms. Secondly, we wanted to
assess if there is any signiﬁcant difference in short and long term
mortality between the 2 approaches.
METHODS A comprehensive search strategy was designed and a thor-
ough computer based search was performed using OVID MEDLINE,
EMBASE and PubMed databases. No time limit to start date was applied
and the search was conducted up to 29 March 2015. We reviewed both
the identiﬁed manuscripts and references cited or citing indexed
studies. Of 1143 citations, 10 studies were included in the analysis.
RESULTS There were a total of 1824 patients with obstructive symp-
tomatic HCM of which 859 (44%) were treated with ASA and 1019 (56%)
with SM. Gender characteristics were available in 8 studies. Fifty-one
percent of patients in both of the groups were men (ASA¼349/677 and
SM¼367/721).The average follow-up in the ASA groupwas 2.9 2 years,
while SM patients were followed up for 4.5  4.4 years. Patients un-
dergoing SM were relatively younger (MD 6.3, 95% CI 3.06 to 9.55, p ¼
0.0001, I2 ¼ 73%) and had higher reduction in the LVOT gradient from
baseline ((MD -9.56, 95%CI -19.15 to 0.04, p¼0.05, I2¼ 95%). However,
there was similar resolution of class III and IV symptoms between the 2
groups (OR 1.21, 95% CI 0.29 to 5.14, p ¼ 0.56, I2 ¼ 0%) . There was no
difference in the sudden cardiac death (SCD) (OR 1.04 95% CI 0.44 –
2.48, p ¼ 0.93, I2 ¼ 0%), short-term (p ¼ 0.36), long-term all cause (OR
0.76 95%CI 0.47 – 1.24, p ¼ 0.27, I2 ¼ 28%) and long-term cardiac mor-
tality (OR 0.74 95% CI 0.26 – 2.14, p ¼ 0.58, I2 ¼ 63%). Patients under-
going ASA had higher incidence of post procedure pacemaker implant
(OR 3.09 95% CI 1.89 – 5.07, p < 0.00001, I2 ¼ 11%) and a repeat proce-
dure (OR 5.68 95% CI 2.59 – 12.47, p < 0.0001, I2 ¼ 0%).
CONCLUSIONS In conclusion, ASA and SM are equally effective to
resolve LVOTO related symptoms in patients diagnosed with HCM.
There is no difference in the early and late mortality between the 2
procedures. Neither there is any difference in the events of SCD. ASA
is less invasive but comes at the cost of higher requirement of pace-
maker implant because of conduction abnormalities post procedure.
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BACKGROUND Alcohol septal ablation (ASA) and surgical myectomy
are invasive treatment options available to patients with drug-re-
fractory, obstructive, hypertrophic cardiomyopathy (HCM). Expert
consensus guidelines recommend myectomy as the ﬁrst line option,
with ASA available for patients at high surgical risk or due to patient
preference. However, there is a paucity of data describing clinical
outcomes following a guideline-based strategy when assessing pa-
tients for invasive septal reduction therapy.
METHODS We sought to deﬁne long-term outcome in HCM patients
undergoing myectomy or ASA in a large HCM referral center, where
management recommendations have been based on 2003 ACC/ESC
and 2011 ACCF/AHA consensus guidelines. Clinical outcomes were
analyzed in 258 consecutive patients who underwent myectomy or
ASA between 2004 and 2012, over a mean follow-up of 4.0  2.2 years.
RESULTS Of the 258 patients, 207 (80%) were referred for myectomy
and 51 (20%) for ASA (40 because of perceived high-risk substrate and 11
due to personal preference). There were no differences at baseline be-
tween the two groups with respect to numerous co-morbidities (COPD,
CVA, diabetes, CKD, liver disease, and metastatic cancer), however,
when compared tomyectomypatients, ASApatientswere older (64 10
vs. 51  15 years; p <0.001), more commonly female (57% vs 41%;
p¼0.06), and had a higher risk score using the modiﬁed Charlson Score
index (3.4  1.4 vs. 2.3  1.4; p<0.001). Compared to ASA, patients who
underwent myectomy achieved a greater improvement in heart failure
symptoms compared to ASA (class I: 58% vs. 33%; p ¼0.003), while the
repeat procedure rate was more common after ASA (0.5% vs. 8%;
p ¼0.006). During follow-up there were 12 deaths, including 10 in pa-
tients who underwent myectomy and 2 following ASA. All-cause mor-
tality was 1.1%/year (0.9%/yr in ASA vs. 1.4%/yr in myectomy patients;p¼0.6) which did not differ when compared with age and gender-
matched US population (p¼0.8) (Figure).
CONCLUSIONS Guideline-based referral for septal reduction therapy
in drug-refractory HCM patients is associated with low mortality rates
for both ASA and myectomy, although there was greater improvement
in limiting heart failure symptoms in the younger, lower-risk myec-
tomy patients. These data substantiate a strategy of decision-making
for invasive septal reduction therapy based on the current expert
consensus guidelines.
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BACKGROUND Many studies have evaluated the safety and efﬁcacy
of alcohol septal ablation (ASA) in symptomatic patients with hyper-
trophic obstructive cardiomyopathy (HOCM), although there are still
no randomised trials, transcatheter ASA is a viable alternative for
patients with HOCM.
METHODS From2009 to 2015 89ASAperformed in 86patients (58males,
28 females)withHOCMatour center.Meanageof pts.was43 [6;76] years.
Temporary pacemaker lead was placed through a femoral or jugular
venous sheath in the right ventricular apex before ASA, also all pts. un-
dergone myocardial contrast echocardiography (MCE) before procedure.
Mean peak pressure gradient (PG) on LVOTwas 93,48,2 mm. Hg. Mitral
valve regurgitation (MR) more than moderate was in all pts. Mean
interventricular septum thickness was 2,5cm [1,6; 3,3].
RESULTS Mean PG on LVOT decreased from 93,48,2 mmHg to
35,34,6 mmHg. The grade of MR reduced from at least moderate to
mild or even trivial. In 3 cases was recorded the complete disap-
pearance of MR. The procedure – related mortality was 0%. In 2 cases
(2,3%) the procedure was aborted by the coronary angiography and
MCE data. Mean follow-up for 86pts (100%) was 684,1 months.
71(83%) pts had PG reduction (to 30 mmHg) – regarded as good result
of procedure. 11 (12,4%) pts had PG > 30mmHg, but signiﬁcant
improvement in symptoms. 1(1,1%) case of sudden death 6 mounts
after procedure. 3(3,5%) pts needed redo procedure due to residual
LVOTO. All redo pts had effective systolic PG decreasing after second
procedure. 6(6,7%) patients had complete AV block and required
